Vamvakas Lambros, Saloustros Emmanouel, Karampeazis Athanasios, Georgoulias Vassilis
Department of Medical Oncology, University Hospital of Heraklion, Heraklion, Crete, Greece.
Clin Lung Cancer. 2009 May;10(3):158-67. doi: 10.3816/CLC.2009.n.022.
Systemic chemotherapy provides improvement in both survival and quality of life for patients with advanced non-small-cell lung cancer (NSCLC). Elderly patients have more comorbidities and tend to tolerate more poorly aggressive chemotherapy and radiation therapy than younger individuals. Our purpose in this article is to summarize recent studies of single-agent chemotherapy and combination regimens with cytotoxic or targeted therapies in the management of elderly patients with advanced NSCLC. We have reviewed the available evidence in the literature to gauge the results of therapy for elderly patients with lung cancer. We found that single-agent chemotherapy remains the standard of care for nonselected elderly patients. Retrospective analyses suggest that the efficacy of platinum-based combination chemotherapy is similar in fit older and younger patients, with increased but acceptable toxicity for elderly patients. Therefore, the outcomes in the fit elderly mirror results observed in younger patients, although toxicity is generally greater.
全身化疗可提高晚期非小细胞肺癌（NSCLC）患者的生存率和生活质量。老年患者合并症更多，与年轻患者相比，往往对积极的化疗和放疗耐受性更差。本文的目的是总结近期关于单药化疗以及细胞毒性或靶向治疗联合方案用于老年晚期NSCLC患者治疗的研究。我们回顾了文献中的现有证据，以评估老年肺癌患者的治疗结果。我们发现，单药化疗仍然是未经过筛选的老年患者的标准治疗方法。回顾性分析表明，铂类联合化疗对身体状况良好的老年和年轻患者疗效相似，老年患者的毒性增加但仍可接受。因此，身体状况良好的老年患者的治疗结果与年轻患者相似，尽管毒性通常更大。
